NucleoCapture is designed to selectively remove neutrophil extracellular traps (NETs) from the bloodstream. In sepsis, where progressive organ dysfunction remains a major driver of mortality, NUC-CAP will evaluate whether removing them translates into clinical benefit.

The multinational, randomized pivotal study is expected to enroll up to 350 patients with sepsis and respiratory failure across the United States and Europe. Patients will be randomized 1:1 to standard of care alone or standard of care with NucleoCapture, with a primary effectiveness endpoint comprising all-cause mortality and organ support-free days through Day 28.